로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Integrin alpha 4 beta 1

Integrin alpha 4 beta 1

요약

Name:Integrin alpha-4/beta-1
Target Synonym:Integrin alpha4beta1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

IT1-H52W1-ELISA
Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag FreeHuman ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) ELISA bioactivity

Immobilized Natalizumab at 1 μg/mL (100 μL/well) can bind Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) with a linear range of 1-16 ng/mL (QC tested).

IT1-H82W1-ELISA
Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag FreeBiotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) ELISA bioactivity

Immobilized Natalizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) with a linear range of 2-31 ng/mL (QC tested).

Synonym Name

Integrin alpha 4 beta 1,ITGA4&ITGB1,ITGA4&B1

Background

Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Carotegrast methyl AJM-300 Approved Ea Pharma, Eisai Co Ltd Carogra Japan Colitis, Ulcerative Ea Pharma Co Ltd 2022-03-28 Colitis, Ulcerative Details
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Tysabri, Antegran, Antegren Japan Multiple Sclerosis Biogen Inc 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Myositis, Inclusion Body; Demyelinating Diseases; Crohn Disease Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
RBx-7796 RBx-7796 Clinical Sun Pharmaceutical Industries Ltd Rhinitis, Allergic; Asthma Details
LLP2A alendronate Phase 1 Clinical University Of California Osteoporosis; Bone Diseases Details
Natalizumab biosimilar (Polpharma Biologics) PB-006 Phase 3 Clinical Polpharma Biologics Multiple Sclerosis, Relapsing-Remitting Details
ATL-1102 ATL-1102; TV-1102; ATL/TV-1102; ISIS-107248 Phase 2 Clinical Ionis Pharmaceuticals Inc Multiple Sclerosis; Muscular Dystrophy, Duchenne Details
7HP-349 7HP-349; 7-HP-349 Details
Firategrast T-0047; SB-683699 Mitsubishi Tanabe Pharma Details

This web search service is supported by Google Inc.

totop